Luciferase complementation-based detection of G-protein-coupled receptor activity

Hideaki Yano^{*,1}, Ning Sheng Cai¹, Jonathan A Javitch^{2,3} & Sergi Ferré¹

¹National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; ²Departments of Psychiatry & Pharmacology, College of Physicians & Surgeons, Columbia University, New York, NY, USA;

³Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY, USA

BioTechniques 65: 9–14 (July 2018) 10.2144/btn-2018-0039

Keywords: assay development • biosensor • complementation • dopamine receptor • GPCR • luciferase

Protein complementation assays (PCA) are used as pharmacological tools, enabling a wide array of applications, ranging from studies of protein–protein interactions to second messenger effects. Methods to detect activities of G protein-coupled receptors (GPCRs) have particular relevance for drug screening. Recent development of an engineered luciferase NanoLuc has created the possibility of generating a novel PCA, which in turn could open a new avenue for developing drug screening assays. Here we identified a novel split position for NanoLuc and demonstrated its use in a series of fusion constructs to detect the activity of GPCRs. The split construct can be applied to a variety of pharmacological screening systems.

Introduction

The protein complementation assays (PCA) approach utilizing various split protein fragments such as fluorescent proteins [1], luciferases [2], and other enzymes [3,4] has been introduced to investigate protein–protein interactions *in vitro* in intact cells. Many of these have been incorporated into pharmacology settings because of their versatility when fused to proteins of interest [5]. Among them, luciferase complementation has been intensively studied in luciferases of various species of origin [6]. These proteins show utility in reliable kinetic measurement, and some split luciferases exhibit reversibility, making them very useful as fusion fragments [7–9].

Currently, PCA-based pharmacological assays rely mostly on a fusion of bulky protein fragments. In addition, the signal brightness of the luciferase complementation approach should be improved, particularly to make it amenable for higher throughput applications. Consequently,

smaller split fragments with brighter signals in a smaller number of cells would make the assay more adaptable. NanoLuc, which was engineered from *Oplophorus* luciferase [10], is superior to other luciferases because of its small size and luminescence intensity [11]. Compared with *Renilla* luciferase (Rluc), it is about half the size (19 vs 36 kDa) and produces luminescence ~150-fold greater [11]. To improve on the shortcomings of previously reported split luciferases of other species (e.g., bulkiness and signal level), we developed a novel bimolecular NanoLuc complementation (BiNC) pair of fragments and investigated their functional properties.

Besides the novelty in PCA tool-making, the BiNC approach is key to advancing the development of robust and compact pharmacology assays. In G-protein coupled receptor (GPCR) drug screening, receptor-G protein coupling as well as G protein subunit rearrangement can be used effectively as ways to measure agonist and antagonist behaviors [12]. While this manuscript was

in preparation, a thorough analysis of split positions for NanoLuc was reported [13]. The split position we selected in this current work happens to be near the residues tested by Dixon *et al.* In the current study, the BiNC fusion is integrated to the GPCR activation scheme mentioned above to develop a variety of novel pharmacology assays beyond protein recruitment to a receptor. The establishment of reliable pharmacological assays in various GPCRs demonstrates the validity and utility of the BiNC approach reported herein.

Materials & methods

DNA constructs & transfection

FRB or FKBP was C-terminally fused to a short linker (SGGGGS) followed by either an Rluc8 N-terminal fragment (L1; residues 1–229), an Rluc8 C-terminal fragment (L2; residues 230–311) [14], a NanoLuc N-terminal fragment (Nluc1; residues 1–97; VFTLEDFVGDWRQTAGYNLDQVLEQG-GVSSLFQNLGVSVPPIQRIVLSGENGLKI-

METHOD SUMMARY

We present a novel series of functional assays for GPCR pharmacology based on bimolecular complementation of NanoLuc, for which activities of at least six different receptors are congruent with previous reports using widely used functional assays. The assays presented herein have significant advantages over conventional ones in terms of reduced molecular steric hindrance and high signal-to-noise ratio. Therefore, fusion constructs are amenable to the application of other protein–protein interactions and the robust signal enables a throughput approach for pharmacological characterization as well as demonstrating their utility in GPCR pharmacology.

DIHVLPYEGLSGDQMGQIEKIFKVVPVD-DHHFKVLHYG), or a NanoLuc C-terminal fragment (Nluc2; residues 98–171; TLVIDGVTPNIMIDYFGRPYEGIAVFDGK-KITVTGTLWNGNKIIDERLINPDGSLFLRV-TINGVTGWRLCERILA). Human receptor constructs, dopamine D1, D2, adrenoceptor β 2A, adenosine A2A and muscarinic M4, were N-terminally fused with a signal peptide followed by a Flag epitope tag for enhanced cell surface expression [15] and their detection [16]. For the split fusions, either L1, L2, Nluc1, or Nluc2 was fused C-terminally. A linker was inserted between the receptor and the split fusion for D1 (made also without the linker), D2 and M4. The following effector constructs were made: $G_{\alpha s}$ -Nluc1 (inserted at residue 67), $G_{\alpha s}$ -Nluc2 (inserted at residue 67), $G_{\alpha i1}$ -Nluc1 (inserted at residue 91), $G_{\alpha i1}$ -Nluc2 (inserted at residue 91), Nluc1-G γ 2, Nluc2-G γ 2 and Nluc2- β -arrestin2. Untagged G β 1, G γ 2 and GPCR kinase 2 (GRK2) were also used for co-transfection. All the constructs were confirmed by sequencing analysis. A constant amount of plasmid cDNA (15 μ g) was transfected into human embryonic kidney cells 293T (HEK-293T) using polyethylenimine (PEI; Sigma-Aldrich, MO, USA) in a 1:2 ratio in 10-cm plates. Cells were maintained in culture with Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and kept in an incubator at 37°C and 5% CO₂. The transfected amount and ratio among the receptor and heterotrimeric G proteins were optimized for the greatest dynamic range in drug-induced luminescence. Experiments were performed approximately 48 h post-transfection.

Luciferase complementation assay

The time course of luciferase complementation was measured by rapamycin (Tocris, Bristol, UK)- and FK506 (Tocris)-induced complex formation and dissociation between FRB-L1 and FKBP-L2, or FRB-Nluc1 and FKBP-Nluc2. Four modes of luciferase complementation assays were performed to detect receptor ligand-induced events for i) Receptor- G_{α} engagement, ii) Receptor-G γ interaction, iii) G_{α} - γ protein activation, and iv) Receptor- β -arrestin2 recruitment. For each configuration, both complementation pairs were tested (i.e., Nluc1 fusion-Nluc2 fusion pair and Nluc2 fusion-Nluc1 fusion pair). Cells were harvested, washed and resuspended

in phosphate-buffered saline (PBS). Approximately 200,000 cells/well were distributed in 96-well plates, and 5 μ M coelenterazine H (Nanolight®, AZ, USA) or 0.03% furimazine (Promega, Southampton, UK) was added to each well. 1 min after addition of coelenterazine H or furimazine, ligands (dopamine [Sigma], L-(-)-norepinephrine [Sigma], 5'-N-Ethylcarboxamidoadenosine [NECA, Tocris], isoproterenol [Tocris], or carbachol [Tocris]) were added to each well. The complemented luminescence was quantified with an open filter for 1 sec using a Mithras LB940 (Berthold Technologies, Bad Wildbad, Germany) after 10 min of substrate incubation. Drug-induced luminescence values are expressed as the basal subtracted luminescence change in the dose-response graphs. Data and statistical analysis were performed with Prism 5 (GraphPad Software).

Results & discussion

Rapid kinetic complementation of novel NanoLuc splits

Based on the previously predicted beta strand repeats [10], which were later confirmed in the crystal structure that emerged during the preparation of this manuscript [17], a split position was chosen at residue 96. In order to assess the suitability of the split position, the amino acid sequences encoding the N-terminal (Nluc1) and C-terminal (Nluc2) fragments were fused C-terminally to FRB and FKBP for testing rapamycin-induced [18,19] BiNC as the macrolide rapamycin induces complex formation between the FRB and FKBP domains (Figure 1A–C). Using the same scheme, Rluc split constructs (*Renilla* luciferase bimolecular complementation [BiRC]) were fused to FRB and FKBP and compared for complementation kinetics (Figure 1E–G). When incubated in 100 nM rapamycin for 3 h, at the end of which the substrate coelenterazine H (5 μ M, a nonsaturating but effective concentration; Supplementary Figure 1A & B) was added, cells expressing the FRB-Nluc1 and the FKBP-Nluc2 showed an increase of 1.74×10^6 counts (arbitrary units), a 5.5-fold increase from the vehicle treated background (Figure 1A, orange). The same fold increase was maintained for over 40 min of detection after the substrate was added while the absolute counts decayed. This increase in BiNC is in contrast to the 1.44×10^4 counts and 24% increase for rapamycin-

treated cells expressing FRB-Rluc1 and FKBP-Rluc2 in the BiRC configuration (Figure 1E, orange). FK506 is a competitive inhibitor for rapamycin and therefore disrupts complex formation between the FRB and FKBP domains. 3-h incubation of 10 μ M FK506 caused only an 8% drop in the average level of luminescence in BiNC (Figure 1A, blue vs black) at 5 min after the substrate addition, indicating that basal level of complex formation can only be reversed very weakly by FK506. A smaller change (2%) by FK506 was observed in BiRC (Figure 1E, blue). Next the competitive inhibition of rapamycin by FK506 was assessed. Addition of 10 μ M FK506 together with 100 nM rapamycin for 3 h decreased the BiNC luminescence by 28% (Figure 1A, red), whereas the co-administration of the drugs only decreased the BiRC luminescence by 3% (Figure 1E, red) showing a partial but substantial degree of competition by FK506 in the BiNC configuration. Stability of the BiNC was tested for the same conditions in the presence of 30 μ g/ml cycloheximide, an inhibitor of protein biosynthesis [20], as newly synthesized luciferase fragments can replenish the complemented pool. Cycloheximide did not cause a significant luminescence change in the response to rapamycin or FK506 treatment (Figure 1A, orange open and blue open) confirming that no new protein synthesis contributed to BiNC formation and BiNC was stable for at least 3 h. Because of its relatively low cost, we carried out the bulk of our assays with coelenterazine H. We also tested the more stable but much more expensive substrate furimazine [11] for its kinetics (Supplementary Figure 1C & D). In this case, BiNC showed a steady level of maintained or slightly increased luminescence over the time period measured. Notably, the rapamycin-induced fold increase in luminescence was similar to that with coelenterazine H, and the remainder of our studies were carried out with coelenterazine H. As expected, with furimazine, BiRC did not yield luminescence as high as BiNC, indicating the preference of substrate-enzyme selectivity.

Next the kinetics of drug-induced BiNC was measured by adding the drugs and substrate at the same time without prior incubation. When added at the same time as coelenterazine H, rapamycin increased the luminescence 2.3-fold (Figure 1B, orange) and FK506 alone decreased

14% (Figure 1B, blue) compared with the vehicle on average between 2–40 min. Interestingly, when FK506 was added 5 min after rapamycin (Figure 1B red), the degree of luminescence drop caused by FK506 (8%) was similar to FK506 alone (Figure 1B blue) indicating that FK506 does not reverse rapamycin's effect. To confirm the lack of luciferase enzyme activity in the individual fragments of Nluc1 and Nluc2, FRB–Nluc1 or FKBP–Nluc2 was expressed separately. As expected, when FRB–Nluc1 or FKBP–Nluc2 was expressed alone, there was no luminescence, nor with vehicle, rapamycin or FK506 treatment (Figure 1C). The same results were observed for FRB–Nluc1 and FKBP–Nluc2 (Figure 1G). Somewhat surprisingly, when FRB–Nluc1-expressing and FKBP–Nluc2-expressing cells were combined in the same well, rapamycin induced a dramatic increase in luminescence compared with vehicle treatment (Figure 1C, black square and light blue square). In comparison, combination of FRB–Nluc1- and FKBP–Nluc2-expressing

cells did not yield much luminescence (Figure 1G, black square and light blue). The complementation happened likely due to the cytosolic protein leaking out to the extracellular space via compromised plasma membrane or potentially from fragments that were secreted. Finally, the specificity of the rapamycin effect was tested by examining the effects of rapamycin on BiNC between two proteins that lack the FKBP and FRB domains. Dopamine receptor D2 (D2R) fused with either Nluc1 or Nluc2 C-terminally was both co-transfected and rapamycin was added. Substantial complementation took place akin to the level of rapamycin-induced FRB–Nluc1 and FKBP–Nluc2 (Figure 1B), but as expected, rapamycin did not cause a significant change in the luminescence. Similar results were observed for the D2R–Nluc fusion complementation counterparts (Figure 1D and H).

NanoLuc complementation-based tools for evaluating G-protein activation

As the chemically induced interaction between the NanoLuc splits was confirmed, BiNC induced by protein–protein interaction was next investigated in the context of GPCR-signaling (Figure 2A). The specificity of protein-protein interaction between dopamine D1 receptor (D1R) and its cognate $G\alpha$ subunit, Gs, was used to explore NanoLuc complementation. Transfection with a fixed amount of D1R–Nluc1 and an increasing amount of co-transfected Gs–Nluc2 led to a dramatic saturable increase in luminescence, whereas FRB–Nluc2, which is not expected to interact with D1R, did not show increased luminescence (Figure 2A). In addition, noncognate G protein coupling (i.e., D1R–Gi and D2R–Gs) was effectively absent without any ligand added (Supplementary Figure 2A). The results indicate that the BiNC can be enhanced by specific protein-protein interactions of fusion proteins.

Next, agonist-induced G protein coupling was studied using an optimized 1:1 transfection ratio between D1R–Nluc1 and Gs–Nluc2. DA-induced luminescence followed a saturable dose–response curve (Figure 2B; $pEC_{50} = 6.78 \pm 0.25$), while noncognate pairs did not show DA-induced luminescence (Supplementary Figure 2B). In a configuration that detects a conformational change related to G protein activation [21], a DA-induced luminescence was measured between Gs–Nluc1 and $G\gamma 2$ –Nluc2 (Figure 2C; $pEC_{50} = 6.96 \pm 0.11$). The result showed a positive BiNC with a similar EC_{50} for DA as the D1R–Nluc1 – Gs–Nluc2 configuration in Figure 2B. The agonist-induced signal increase in Gs– $G\gamma 2$ configuration is in agreement with other studies [12,21,22]. To further characterize the conformational change within the D1R–G protein complex, an agonist-induced change between D1R–Nluc1 and $G\gamma 2$ –Nluc2 was measured (Figure 2D; $pEC_{50} = 7.78 \pm 0.16$). Interestingly, in this configuration, DA caused a drop in luminescence indicating either dissociating movement or chromophore rearrangement between the receptor and γ subunit. Nonetheless, the pEC_{50} values of all the different configurations report in a relatively tight range between 6.78 and 7.78, indicating similar drug-induced conformational changes among different fusion constructs, albeit with somewhat different apparent potencies. The recruitment of the signaling protein, β -arrestin, was also studied (Figure 2E; $pEC_{50} = 6.00 \pm 0.10$).

Figure 1. Drug-induced complementation of split luciferase fragments. Throughout, time scale corresponds to substrate (5 μ M coelenterazine H) incubation time. **(A)** Kinetic measurement of NanoLuc complementation between FRB–Nluc1 and FKBP–Nluc2 after 3 h of incubation with vehicle (black), 100 nM rapamycin (orange), 10 μ M FK506 (blue), 100 nM rapamycin + 10 μ M FK506 (red), 30 μ g/ml cycloheximide + vehicle (black open), 30 μ g/ml cycloheximide + 100 nM rapamycin (orange open), 30 μ g/ml cycloheximide + 10 μ M FK506 (blue open). **(B)** Kinetic measurement of NanoLuc complementation between FRB–Nluc1 and FKBP–Nluc2 with simultaneous addition of vehicle (black), 100 nM rapamycin (orange), 10 μ M FK506 (blue), 100 nM rapamycin + 10 μ M FK506 added after 5 min (red). **(C)** Time-dependent drug-induced change of NanoLuc activity in cells separately expressing split fragments immediately after addition of vehicle with FRB–Nluc1 fragment (black top hemi circle), 100 nM rapamycin with FRB–Nluc1 fragment (orange top hemi circle), 10 μ M FK506 with FRB–Nluc1 fragment (blue top hemi circle), vehicle with FKBP–Nluc2 fragment (black bottom hemi circle), 100 nM rapamycin with FKBP–Nluc2 fragment (orange bottom hemi circle), 10 μ M FK506 with FKBP–Nluc2 fragment (blue bottom hemi circle), vehicle with FRB–Nluc1 fragment cells and FKBP–Nluc2 fragment cells combined (black square), and 100 nM rapamycin with FRB–Nluc1 fragment cells and FKBP–Nluc2 fragment cells combined (light blue square). **(D)** NanoLuc complementation between D2R–Nluc1 and D2R–Nluc2 immediately after 3 h of incubation with vehicle (black), and 100 nM rapamycin (orange). **(E–H)** Nluc complementation (same experimental scheme and legend for A–D applied).

As expected, DA caused a luminescence increase in D1R-Nluc1 and β -arrestin 2-Nluc2 transfected cells, with slow kinetics consistent with the expected time frame of arrestin recruitment (data not shown).

The BiNC configurations shown in Figure 2 were then tested for complementation using constructs in which Nluc1 and Nluc2 were reversed. As shown in the first column of Figure 3, fusion replacement between Nluc1 and Nluc2 (e.g., D1N1–GsN2 vs D1N2–GsN1, D1N1– γ 2N2 vs D1N2– γ 2N1) results in the same directionality of agonist-induced response except for GsN1– γ 2N2 vs GsN2– γ 2N1 in which GsN2– γ 2N1 showed a time-dependent luminescence change in directionality of the agonist response from negative- to positive-induction.

In order to validate the coupling findings and build pharmacological tools for different receptors, we made a series of constructs

harboring Nluc1 and Nluc2 fusion in Gs- and Gi-coupled receptors (Figure 3). Consistently, other Gs-coupled receptors, β 2 adrenergic receptor (β 2AR) and adenosine A2A receptor (A2AR), showed similar patterns of BiNC change as D1R. By contrast, Gi-coupled receptors (dopamine D2 receptor [D2R] and muscarinic M4 receptor [M4R]) showed quite different patterns of BiNC compared with the Gs-coupled receptors, consistent with their expected coupling to Gi. The receptor–G α and receptor–G γ configurations showed agonist-induced BiNC consistent with the conformational change involved in receptor engagement (Figure 3 first four rows for D2R and M4R). In a G-protein activation configuration, Gi–G γ 2 showed a negative BiNC indicative of distancing or dissociating movement between the two and in agreement with previous reports [12,21,22].

Pharmacological assessment of split receptor-G protein tools

Finally, the capability to parse out and characterize ligands with different pharmacological properties was tested in the receptor-G α configuration for both Gs- and Gi-coupled receptors (Figure 4). For D1R, relative to DA (pEC₅₀ = 6.78 $\pm$ 0.25), the potency profile could be clearly differentiated between less potent norepinephrine (pEC₅₀ = 5.90 $\pm$ 0.21) and highly potent A77636 (pEC₅₀ = 9.74 $\pm$ 0.25). In terms of efficacy, a partial agonist SKF38393 showed the expected lower efficacy (48.5% of DA). A selective D1R antagonist SCH23390 counteracted 10 μ M DA pre-activation and gave a negative BiNC change relative to the pre-activation level, consistent with inverse agonist activity. The antagonist also exhibited a high potency (pIC₅₀ = 9.22 $\pm$ 0.42). All of the characteristics of D1R ligands are in agreement with previous reports [23,24]. D2R pharmacology was also in agreement with a previous study [25], in that norepinephrine showed less potency (pEC₅₀ = 5.22 $\pm$ 0.14) relative to DA (pEC₅₀ = 6.61 $\pm$ 0.10) and a selective D2R antagonist eticlopride showed complete blockade of 10 μ M DA pre-activation and high potency (pIC₅₀ = 9.47 $\pm$ 0.46). Albeit narrower luminescence drug-induced ranges, furimazine showed similar potencies and efficacies (Supplementary Figure 2C & D). Taken together, for both Gs-coupled (D1R) and Gi-coupled (D2R) receptors, the receptor-G α BiNC configuration can be used to assess pharmacological properties of ligands.

When compared with the BiRC, in addition to the smaller fragment sizes (i.e., 95 and 63 amino acids for Nluc1 and Nluc2 versus 229 and 83 amino acids for Rluc1 and Rluc2), the rapamycin-induced activity increase of BiNC-fusion constructs was more pronounced (5.5-fold compared with 1.2-fold for BiRC) and more kinetically responsive (135% increase after 2 min of rapamycin addition compared with 4% increase for BiRC). These characteristics show the clear advantages of BiNC over BiRC. Coincidentally, while preparing this manuscript, both a crystal structure [17] and new BiNC split positions [13] of NanoLuc were published. This split position was tested in the arrestin recruitment assay but not assessed for G-protein activation.

Equally important to the enzymatic properties of BiNC is its applicability in functionally relevant fusion constructs.

		D1	D1-linker	β 2A	A2A	D2-linker	M4-linker
	RN1-GaN2	+	+	+	+	+	+
	RN2-GaN1	+	+	+	+	+	+
	RN1-GyN2	-	-	-	-	+	+
	RN2-GyN1	-	-	-	-	+	0
	GaN1-GyN2	+ ^a	NA	+ ^a	+ ^a	- ^a	- ^a
	GaN2-GyN1	- -> + ^a	NA	- -> + ^a	0 -> + ^a	- ^a	- ^a

Figure 3. Agonist-induced complementation change between various combinations of Nluc1- and Nluc2-fusion constructs (top–bottom) for G α s- and G α i-coupled receptors (left–right). Signs indicate the drug-induced luminescence change (-, 0, +) determined by 2, 10, 20, 30 min reading of dose effect curves (basal to 100 μ M agonist). - $\rightarrow$ + or 0 $\rightarrow$ + = sign changing over 20 min. D1-, D2-, or M4-linker = linker (GGGGSGGGSGGGGS) inserted between the receptor and NanoLuc fragment fusion. a = receptor with no NanoLuc fragment fusion is used.

DA (D1 and D2), isoproterenol (β 2A), NECA (A2A), or carbachol (M4) was used as a corresponding agonist.

pEC₅₀: D1Nluc1 GsNluc2 – 6.78–7.77; D1-linkerNluc1 GsNluc2 – 6.17–7.43; β 2ANluc1 GsNluc2 – 7.79–8.04; A2ANluc1 GsNluc2 – 6.68–6.87; D2-linkerNluc1 GiNluc2 – 6.15–7.35; M4-linkerNluc1 GiNluc2 – 5.89–6.95.

NA: Not available.

To this end, we evaluated five different Gs- and Gi-coupled receptors. As shown in Figure 3, the potencies were within a relatively tight range among the different configurations tested showing the utility of the diverse modes of detection of

luminescence complementation. The EC₅₀ values were also in close agreement with reports using different methods for measuring G-protein activation and receptor engagement [26–28]. Overall, for the D1R and D2R, the potencies and efficacies

of tested ligands were in agreement with previous reports [23,25,29,30], indicating the utility of the assay configuration for testing pharmacology of other receptors. It also needs to be pointed out that in this study coelenterazine H, as opposed to furimazine, was mainly used to characterize the complementation assays since coelenterazine H is much more cost-effective and affords a very good dynamic range. Overall, the current study demonstrates that BiNC-fusion constructs of receptor–effector pairs can be used as an effective method to assay pharmacological properties of ligands that can be expanded to a higher throughput approach.

Author contributions

H.Y. conceived, designed and performed all of the experiments and related data analysis. N.S.C. assisted with the molecular cloning work. H.Y. and J.A.J. wrote the manuscript and all the authors contributed in revision of the manuscript.

Financial & competing interests disclosure

This work was supported by the Intramural funds of the National Institute on Drug Abuse (S.F.) and a fellowship from the Japan Society for the Promotion of Science (H.Y.). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Open access

This work is licensed under the Creative Commons Attribution 4.0 License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.future-science.com/doi/suppl/10.2144/btn-2018-0039

Figure 4. Confirmation of pharmacological characteristics in drug-induced G-protein engagement. (A) D1-Nluc1 G α s-Nluc2 engagement with dopamine (black), norepinephrine (orange), SKF38393 (blue), A77636 (red), 10 μ M DA + SCH23390 (open black). **(B)** D2-Nluc1 G α i-Nluc2 engagement with dopamine (black), norepinephrine (orange), 10 μ M DA + eticlopride (open black).

References

- Kerppola TK. Bimolecular fluorescence complementation (BiFC) analysis as a probe of protein interactions in living cells. *Annu. Rev. Biophys.* 37(1), 465–487 (2008).
- Azad T, Tashakor A, Hosseinkhani S. Split-luciferase complementary assay: applications, recent developments, and future perspectives. *Anal. Bioanal. Chem.* 406(23), 5541–5560 (2014).
- Kerppola TK. Complementary methods for studies of protein interactions in living cells. *Nat. Meth.* 3(12), 969–971 (2006).
- Remy I, Michnick SW. Application of protein-fragment complementation assays in cell biology. *Biotechniques* 42(2), 137–145 (2007).
- Morell M, Ventura S, Aviles FX. Protein complementation assays: approaches for the *in vivo* analysis of protein interactions. *FEBS Lett.* 583(11), 1684–1691 (2009).
- Thorne N, Inglese J, Auld DS. Illuminating insights into firefly luciferase and other bioluminescent reporters used in chemical biology. *Chem. & Biol.* 17(6), 646–657 (2010).
- Stefan E, Aquin S, Berger N *et al.* Quantification of dynamic protein complexes using Renilla luciferase fragment complementation applied to protein kinase A activities *in vivo*. *Proc. Natl Acad. Sci.* 104(43), 16916–16921 (2007).
- Villalobos V, Naik S, Bruinsma M *et al.* Dual-color click beetle luciferase heteroprotein fragment complementation assays. *Chem. Biol.* 17(9), 1018–1029 (2010).
- Remy I, Michnick SW. A highly sensitive protein-protein interaction assay based on Gaussia luciferase. *Nat. Meth.* 3(12), 977–979 (2006).
- Inouye S, Sasaki S. Overexpression, purification and characterization of the catalytic component of *Oplophorus* luciferase in the deep-sea shrimp, *Oplophorus gracilirostris*. *Protein Expr. Purif.* 56(2), 261–268 (2007).
- Hall MP, Unch J, Binkowski BF *et al.* Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. *ACS Chem. Biol.* 7(11), 1848–1857 (2012).
- Gales C, Rebois RV, Hogue M *et al.* Real-time monitoring of receptor and G-protein interactions in living cells. *Nat. Meth.* 2(3), 177–184 (2005).
- Dixon AS, Schwinn MK, Hall MP *et al.* NanoLuc complementation reporter optimized for accurate measurement of protein interactions in cells. *ACS Chem. Biol.* 11(2), 400–408 (2016).
- Paulmurugan R, Gambhir SS. Monitoring protein–protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. *Anal. Chem.* 75(7), 1584–1589 (2003).
- Guan XM, Tong Sun K, Kobilka BK. Enhancement of membrane insertion and function in a type IIIb membrane protein following introduction of a cleavable signal peptide. *J. Biol. Chem.* 267(31), 21995–21998 (1992).
- Guo W, Urizar E, Kralikova M *et al.* Dopamine D2 receptors form higher order oligomers at physiological expression levels. *EMBO J.* doi:10.1038/emboj.2008.153 (2008).
- Tomabechi Y, Hosoya T, Ehara H, Sekine S-I, Shirouzu M, Inouye S. Crystal structure of nanoKAZ: The mutated 19 kDa component of *Oplophorus* luciferase catalyzing the bioluminescent reaction with coelenterazine. *Biochem. Biophys. Res. Commun.* 470(1), 88–93 (2016).
- Remy I, Michnick SW. Clonal selection and *in vivo* quantitation of protein interactions with protein-fragment complementation assays. *Proc. Natl Acad. Sci.* 96(10), 5394–5399 (1999).
- Liberles SD, Diver ST, Austin DJ, Schreiber SL. Inducible gene expression and protein translocation using nontoxic ligands identified by a mammalian three-hybrid screen. *Proc. Natl Acad. Sci.* 94(15), 7825–7830 (1997).
- Helinek TG, Devlin TM, Ch'ih JJ. Initial inhibition and recovery of protein synthesis in cycloheximide-treated hepatocytes. *Biochem. Pharmacol.* 31(7), 1219–1225 (1982).
- Gales C, Van Durm JJ, Schaak S *et al.* Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. *Nat. Struct. Mol. Biol.* 13(9), 778–786 (2006).
- Frederick AL, Yano H, Trifilieff P *et al.* Evidence against dopamine D1/D2 receptor heteromers. *Mol. Psych.* doi:10.1038/mp.2014.166 (2015).
- Zhang J, Xiong B, Zhen X, Zhang A. Dopamine D1 receptor ligands: where are we now and where are we going. *Med. Res. Rev.* 29(2), 272–294 (2009).
- Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit β -arrestin or promote internalization of the D1 dopamine receptor. *ACS Chem. Neurosci.* 6(4), 681–692 (2015).
- Sánchez-Soto M, Bonifazi A, Cai NS *et al.* Evidence for noncanonical neurotransmitter activation: norepinephrine as a dopamine D2-Like receptor agonist. *Mol. Pharmacol.* 89(4), 457–466 (2016).
- Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes – characterization of stably transfected receptors in CHO cells. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 369(2), 151–159 (2004).
- Dionisotti S, Ongini E, Zocchi C, Kull B, Arslan G, Fredholm BB. Characterization of human A(2A) adenosine receptors with the antagonist radioligand [3H]-SCH 58261. *Br. J. Pharmacol.* 121(3), 353–360 (1997).
- Figueroa KW, Griffin MT, Ehler FJ. Selectivity of agonists for the active state of M(1) to M(4) muscarinic receptor subtypes. *J. Pharmacol. Exp. Ther.* 328(1), 331–342 (2009).
- Sunahara RK, Guan H-C, O'Dowd BF *et al.* Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. *Nature* 350(6319), 614–619 (1991).
- Toll L, Berzetei-Gurske IP, Polgar WE *et al.* Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. *NIDA Res. Monogr.* 178, 440–466 (1998).

First draft submitted: 2 October 2017; Accepted for publication: 15 May 2018

Address correspondence to: Hideaki Yano; National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; Tel.: +1 443 740 2612; E-mail: yano@nih.gov

To purchase reprints of this article contact:
s.cavana@future-science.com